RightFit
RecruitingPhase not listed

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 115 Years
Sex
Male only
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at treatments, health results, and patient traits in adults with advanced prostate cancer in US medical care. The cancer has spread and keeps growing despite treatment to lower testosterone, a male hormone. The study uses health data from the PRECISION data platform.

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • First diagnosed with this type of prostate cancer between January 1, 2021, and December 31, 2025.
  • Male when first diagnosed with this type of prostate cancer.
  • Age 18 when first diagnosed with this type of prostate cancer.

Who can't join

    Simplified for readability. The official criteria below are what the study team uses.

    Official eligibility criteria

    Inclusion criteria: * Diagnosis of mCRPC between 01 January 2021 and 31 December 2025. * Male sex at index, where index is the date of initial mCRPC diagnosis. * Age 18 years at index. Exclusion criteria: • None

    Study sites (1)

    NJ